Most people don’t enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Good afternoon and welcome everyone to the GeoVax Third Quarter 2024 Corporate Update Call. My name is Michelle and I will facilitate today ...

A groundbreaking study introduces stable inhalable mRNA treatment using nanoparticles that hold up during nebulization, ...

The world's first bivalent mRNA vaccine candidate against respiratory syncytial virus, or RSV, kicked off Phase I clinical ...

The study demonstrates that activating the vitamin D receptor (VDR) with calcitriol suppresses cell proliferation in ...

Commenting on the quarter Dr. Alexander Zehnder, Chief Executive Officer of CureVac (CVAC) said: “The third quarter was truly ...

Not long after netting $57m in financing, Inflammatix has kick started a clinical trial evaluating its technology for the ...

Trace Neuroscience Launches with $101 Million Series A Financing to Expand Genomic Medicine for Neurodegenerative Diseases, ...

There is no evidence Japan has named the COVID-19 vaccine the “most deadly drug in history,” as the post claims.

Reactogenicity is comparable for simultaneous and sequential administration of mRNA COVID-19 and influenza vaccines.

Brad Miller, Moderna's CIO, has driven technology innovation to help drive continued gains for the roughly $7 billion revenue ...

“Arcturus is actively engaged with the U.S. government to prepare for the next pandemic, and clearance to proceed into the clinic with our STARR® self-amplifying mRNA technology is a key step in this ...